Taiwan Liposome Co (TLC, 台灣微脂體) rose nearly 76 percent on its trading debut on the GRETAI Securities Market yesterday, after raising NT$729.96 million (US$25.07 million) in its initial public offering (IPO).
After transferring their listing from the emerging board, Taiwan Liposome shares closed at NT$278 per share on its first day of GRETAI trading and at one point rose as high as NT$288, compared to its IPO price of NT$158. The benchmark over-the-counter index ended the day 0.56 percent lower.
On Thursday, the developer of generic drugs used to treat breast and ovarian cancer, as well as peripheral vascular disease, saw its shares end at NT$270.51 on the emerging board. The stock has risen 311.85 percent so far this year, according to the Taiwan Stock Exchange’s data.
Taiwan Liposome, headquartered in Taipei’s Nangang Software Park (南港軟體園區), issued 4.62 million new shares at this IPO. The company said earlier it planned to use the share-sale proceeds to improve its gross margin and strengthen its bottom line.
Taiwan Liposome focuses on the research and development of pharmaceutical products based on its lipid-based drug delivery technologies to cure infected body parts while reducing toxicity from the drugs.
The company’s products can be put into three categories: super generic drugs (including cancer drugs Doxisome and AmBil), new formulation drugs (like ProFlow for vascular disease) and new chemical entity drugs (such as liver cancer drug Lipotecan).
In March, the company signed a collaboration pact with Teva Pharmaceutical Industries Ltd, agreeing to license the distribution right for Taiwan Liposome’s generic cancer products, including Doxisome, for the US territory to the Israeli company.
Fubon Securities Investment Services Co (富邦投顧) yesterday said the company’s proprietary drug delivery technologies are globally competitive, while its generic drugs Doxisome and AmBil appear very likely to go on the market in near future, which would bring in handsome revenue to the firm.
Taiwan Liposome reported a net income of NT$24.3 million, or earnings per share of NT$0.62, in the third quarter, after posting a net loss of NT$40.69 million, or a net loss per share of NT$1.04 per share, in the first half of the year, company data showed.
Fubon Securities analyst Heather Chang (張雅雯) said the brokerage forecast Taiwan Liposome’s net profit would expand 689 percent to NT$300 million (NT$6.83 per share) next year, from an estimated NT$38 million (NT$0.86 per share) this year, while revenue will rise to NT$648 million from NT$280 millio thanks to the collection of certain milestone payments from Doxisome and royalty payments from AmBil and ProFlow.
“Teva would likely apply for the Food and Drug Administration’s permission to market Doxisome in the US during the first half of next year and brings the drug to the market in 2014,” Chang said in a note. “Once Doxisome enters the market in 2014, the drug’s royalty payments could boost the company’s net profit to NT$680 million (NT$15.46 per share) in 2014 and NT$1.1 billion (NT$25 per share) in 2015.”
Meanwhile, the company has received regulatory approval to sell ProFlow drug in the Taiwanese market and partnered with pharmaceutical firms in Japan and South Korea to sell the drug there next year at the earliest, she said.
purpose: Tesla’s CEO sought to meet senior Chinese officials to discuss the rollout of its ‘full self-driving’ software in China and approval to transfer data they had collected Tesla Inc CEO Elon Musk arrived in Beijing yesterday on an unannounced visit, where he is expected to meet senior officials to discuss the rollout of "full self-driving" (FSD) software and permission to transfer data overseas, according to a person with knowledge of the matter. Chinese state media reported that he met Premier Li Qiang (李強) in Beijing, during which Li told Musk that Tesla's development in China could be regarded as a successful example of US-China economic and trade cooperation. Musk confirmed his meeting with the premier yesterday with a post on social media platform X. "Honored to meet with Premier Li
Dutch brewing company Heineken NV on Friday announced an investment of NT$13.5 billion (US$414.62 million) over the next five years in Taiwan. The first multinational brewing company to operate in Taiwan, Heineken made the statement at a ceremony held at its brewery in Pingtung County. It also outlined its efforts to make the brewery “net zero” by 2030. Heineken has been in the Taiwanese market for 20 years, Heineken Taiwan managing director Jeff Wu (吳建甫) said. With strong support from local consumers, the Dutch brewery decided to transition from sales to manufacturing in the country, Wu said. Heineken assumed majority ownership and management rights
ARTIFICIAL INTELLIGENCE: The chipmaker last month raised its capital spending by 28 percent for this year to NT$32 billion from a previous estimate of NT$25 billion Contract chipmaker Powerchip Semiconductor Manufacturing Corp (力積電子) yesterday launched a new 12-inch fab, tapping into advanced chip-on-wafer-on-substrate (CoWoS) packaging technology to support rising demand for artificial intelligence (AI) devices. Powerchip is to offer interposers, one of three parts in CoWoS packaging technology, with shipments scheduled for the second half of this year, Powerchip chairman Frank Huang (黃崇仁) told reporters on the sidelines of a fab inauguration ceremony in the Tongluo Science Park (銅鑼科學園區) in Miaoli County yesterday. “We are working with customers to supply CoWoS-related business, utilizing part of this new fab’s capacity,” Huang said, adding that Powerchip intended to bridge
Microsoft Corp yesterday said that it would create Thailand’s first data center region to boost cloud and artificial intelligence (AI) infrastructure, promising AI training to more than 100,000 people to develop tech. Bangkok is a key economic player in Southeast Asia, but it has lagged behind Indonesia and Singapore when it comes to the tech industry. Thailand has an “incredible opportunity to build a digital-first, AI-powered future,” Microsoft chairman and chief executive officer Satya Nadella said at an event in Bangkok. Data center regions are physical locations that store computing infrastructure, allowing secure and reliable access to cloud platforms. The global embrace of AI